-
Autor
Campbell, Philip 1 Carson, Robin 1 Cavo, Michele 1 Chiu, Christopher 1 Cook, Mark 1 Crepaldi, Andre 1 Crist, Wendy 1 Deraedt, William 1 Dimopoulos, Meletios A 1 Doyen, Chantal 1 Fujisaki, Tomoaki 1 Garg, Mamta 1 Grosicki, Sebastian 1 Iosava, Genadi 1 Jakubowiak, Andrzej 1 Kaplan, Polina 1 Knop, Stefan 1 Liberati, Anna M 1 Lucio, Paulo 1 Mateos, María-Victoria 1
-
Pracoviště
Andrew Love Cancer Centre Geelong VIC... 1 Champalimaud Center for the Unknown L... 1 Clinic of Professional Pathology Sara... 1 Clínica de Tratamento E Cuiaba Brazil 1 Dnepropetrovsk City Clinical Hospital... 1 From University Hospital of Salamanca... 1 Janssen Research and Development Rari... 1 Janssen Research and Development Spri... 1 Japanese Red Cross Medical Center Dep... 1 LTD Medinvent Institute of Health Tbi... 1 Matsuyama Red Cross Hospital Matsuyam... 1 National and Kapodistrian University ... 1 Semmelweis Egyetem Budapest Hungary 1 University Hospital Brno Brno Czech R... 1 University Hospitals Birmingham NHS F... 1 University of Chicago Medical Center ... 1 Université Catholique de Louvain both... 1 Würzburg University Medical Center Wü... 1 the Department of Cancer Prevention S... 1 the Department of Internal Medicine S... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
-
Autor
Campbell, Philip 1 Carson, Robin 1 Cavo, Michele 1 Chiu, Christopher 1 Cook, Mark 1 Crepaldi, Andre 1 Crist, Wendy 1 Deraedt, William 1 Dimopoulos, Meletios A 1 Doyen, Chantal 1 Fujisaki, Tomoaki 1 Garg, Mamta 1 Grosicki, Sebastian 1 Iosava, Genadi 1 Jakubowiak, Andrzej 1 Kaplan, Polina 1 Knop, Stefan 1 Liberati, Anna M 1 Lucio, Paulo 1 Mateos, María-Victoria 1
-
Pracoviště
Andrew Love Cancer Centre Geelong VIC... 1 Champalimaud Center for the Unknown L... 1 Clinic of Professional Pathology Sara... 1 Clínica de Tratamento E Cuiaba Brazil 1 Dnepropetrovsk City Clinical Hospital... 1 From University Hospital of Salamanca... 1 Janssen Research and Development Rari... 1 Janssen Research and Development Spri... 1 Japanese Red Cross Medical Center Dep... 1 LTD Medinvent Institute of Health Tbi... 1 Matsuyama Red Cross Hospital Matsuyam... 1 National and Kapodistrian University ... 1 Semmelweis Egyetem Budapest Hungary 1 University Hospital Brno Brno Czech R... 1 University Hospitals Birmingham NHS F... 1 University of Chicago Medical Center ... 1 Université Catholique de Louvain both... 1 Würzburg University Medical Center Wü... 1 the Department of Cancer Prevention S... 1 the Department of Internal Medicine S... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
-
Mateos, María-Victoria
Autor Mateos, María-Victoria From University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca (M.-V.M.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona (J.S.-M.) - both in Spain National and Kapodistrian University of Athens, Athens (M.A.D.) the Institute of Hematology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera "Santa Maria," Terni (A.M.L.) - both in Italy Japanese Red Cross Medical Center, Department of Hematology, Tokyo (K.S.) University of Chicago Medical Center, Chicago (A.J.) Würzburg University Medical Center, Würzburg, Germany (S.K.) Université Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both in Belgium Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.) Semmelweis Egyetem, Budapest, Hungary (Z.N.) Dnepropetrovsk City Clinical Hospital #4, Dnepropetrovsk, Ukraine (P.K.) University Hospital Brno, Brno, Czech Republic (L.P.) University Hospitals Birmingham NHS Foundation Trust, Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.) - both in the United Kingdom the Department of Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland (S.G.) Clínica de Tratamento E, Cuiaba, Brazil (A.C.) Andrew Love Cancer Centre, Geelong, VIC, Australia (P.C.) Clinic of Professional Pathology, Saratov, Russia (T.S.) the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.) LTD "Medinvent" Institute of Health, Tbilisi, Georgia (G.I.) Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.) Janssen Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.) and Janssen Research and Development, Raritan, NJ (J.W., H.N.)
-
Dimopoulos, Meletios A
Autor Dimopoulos, Meletios A From University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca (M.-V.M.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona (J.S.-M.) - both in Spain National and Kapodistrian University of Athens, Athens (M.A.D.) the Institute of Hematology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera "Santa Maria," Terni (A.M.L.) - both in Italy Japanese Red Cross Medical Center, Department of Hematology, Tokyo (K.S.) University of Chicago Medical Center, Chicago (A.J.) Würzburg University Medical Center, Würzburg, Germany (S.K.) Université Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both in Belgium Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.) Semmelweis Egyetem, Budapest, Hungary (Z.N.) Dnepropetrovsk City Clinical Hospital #4, Dnepropetrovsk, Ukraine (P.K.) University Hospital Brno, Brno, Czech Republic (L.P.) University Hospitals Birmingham NHS Foundation Trust, Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.) - both in the United Kingdom the Department of Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland (S.G.) Clínica de Tratamento E, Cuiaba, Brazil (A.C.) Andrew Love Cancer Centre, Geelong, VIC, Australia (P.C.) Clinic of Professional Pathology, Saratov, Russia (T.S.) the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.) LTD "Medinvent" Institute of Health, Tbilisi, Georgia (G.I.) Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.) Janssen Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.) and Janssen Research and Development, Raritan, NJ (J.W., H.N.)
-
Cavo, Michele
Autor Cavo, Michele From University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca (M.-V.M.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona (J.S.-M.) - both in Spain National and Kapodistrian University of Athens, Athens (M.A.D.) the Institute of Hematology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera "Santa Maria," Terni (A.M.L.) - both in Italy Japanese Red Cross Medical Center, Department of Hematology, Tokyo (K.S.) University of Chicago Medical Center, Chicago (A.J.) Würzburg University Medical Center, Würzburg, Germany (S.K.) Université Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both in Belgium Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.) Semmelweis Egyetem, Budapest, Hungary (Z.N.) Dnepropetrovsk City Clinical Hospital #4, Dnepropetrovsk, Ukraine (P.K.) University Hospital Brno, Brno, Czech Republic (L.P.) University Hospitals Birmingham NHS Foundation Trust, Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.) - both in the United Kingdom the Department of Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland (S.G.) Clínica de Tratamento E, Cuiaba, Brazil (A.C.) Andrew Love Cancer Centre, Geelong, VIC, Australia (P.C.) Clinic of Professional Pathology, Saratov, Russia (T.S.) the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.) LTD "Medinvent" Institute of Health, Tbilisi, Georgia (G.I.) Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.) Janssen Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.) and Janssen Research and Development, Raritan, NJ (J.W., H.N.)
-
Suzuki, Kenshi
Autor Suzuki, Kenshi From University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca (M.-V.M.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona (J.S.-M.) - both in Spain National and Kapodistrian University of Athens, Athens (M.A.D.) the Institute of Hematology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera "Santa Maria," Terni (A.M.L.) - both in Italy Japanese Red Cross Medical Center, Department of Hematology, Tokyo (K.S.) University of Chicago Medical Center, Chicago (A.J.) Würzburg University Medical Center, Würzburg, Germany (S.K.) Université Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both in Belgium Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.) Semmelweis Egyetem, Budapest, Hungary (Z.N.) Dnepropetrovsk City Clinical Hospital #4, Dnepropetrovsk, Ukraine (P.K.) University Hospital Brno, Brno, Czech Republic (L.P.) University Hospitals Birmingham NHS Foundation Trust, Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.) - both in the United Kingdom the Department of Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland (S.G.) Clínica de Tratamento E, Cuiaba, Brazil (A.C.) Andrew Love Cancer Centre, Geelong, VIC, Australia (P.C.) Clinic of Professional Pathology, Saratov, Russia (T.S.) the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.) LTD "Medinvent" Institute of Health, Tbilisi, Georgia (G.I.) Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.) Janssen Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.) and Janssen Research and Development, Raritan, NJ (J.W., H.N.)
-
Jakubowiak, Andrzej
Autor Jakubowiak, Andrzej From University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca (M.-V.M.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona (J.S.-M.) - both in Spain National and Kapodistrian University of Athens, Athens (M.A.D.) the Institute of Hematology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera "Santa Maria," Terni (A.M.L.) - both in Italy Japanese Red Cross Medical Center, Department of Hematology, Tokyo (K.S.) University of Chicago Medical Center, Chicago (A.J.) Würzburg University Medical Center, Würzburg, Germany (S.K.) Université Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both in Belgium Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.) Semmelweis Egyetem, Budapest, Hungary (Z.N.) Dnepropetrovsk City Clinical Hospital #4, Dnepropetrovsk, Ukraine (P.K.) University Hospital Brno, Brno, Czech Republic (L.P.) University Hospitals Birmingham NHS Foundation Trust, Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.) - both in the United Kingdom the Department of Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland (S.G.) Clínica de Tratamento E, Cuiaba, Brazil (A.C.) Andrew Love Cancer Centre, Geelong, VIC, Australia (P.C.) Clinic of Professional Pathology, Saratov, Russia (T.S.) the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.) LTD "Medinvent" Institute of Health, Tbilisi, Georgia (G.I.) Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.) Janssen Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.) and Janssen Research and Development, Raritan, NJ (J.W., H.N.)
-
Knop, Stefan
Autor Knop, Stefan From University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca (M.-V.M.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona (J.S.-M.) - both in Spain National and Kapodistrian University of Athens, Athens (M.A.D.) the Institute of Hematology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera "Santa Maria," Terni (A.M.L.) - both in Italy Japanese Red Cross Medical Center, Department of Hematology, Tokyo (K.S.) University of Chicago Medical Center, Chicago (A.J.) Würzburg University Medical Center, Würzburg, Germany (S.K.) Université Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both in Belgium Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.) Semmelweis Egyetem, Budapest, Hungary (Z.N.) Dnepropetrovsk City Clinical Hospital #4, Dnepropetrovsk, Ukraine (P.K.) University Hospital Brno, Brno, Czech Republic (L.P.) University Hospitals Birmingham NHS Foundation Trust, Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.) - both in the United Kingdom the Department of Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland (S.G.) Clínica de Tratamento E, Cuiaba, Brazil (A.C.) Andrew Love Cancer Centre, Geelong, VIC, Australia (P.C.) Clinic of Professional Pathology, Saratov, Russia (T.S.) the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.) LTD "Medinvent" Institute of Health, Tbilisi, Georgia (G.I.) Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.) Janssen Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.) and Janssen Research and Development, Raritan, NJ (J.W., H.N.)
-
Doyen, Chantal
Autor Doyen, Chantal From University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca (M.-V.M.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona (J.S.-M.) - both in Spain National and Kapodistrian University of Athens, Athens (M.A.D.) the Institute of Hematology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera "Santa Maria," Terni (A.M.L.) - both in Italy Japanese Red Cross Medical Center, Department of Hematology, Tokyo (K.S.) University of Chicago Medical Center, Chicago (A.J.) Würzburg University Medical Center, Würzburg, Germany (S.K.) Université Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both in Belgium Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.) Semmelweis Egyetem, Budapest, Hungary (Z.N.) Dnepropetrovsk City Clinical Hospital #4, Dnepropetrovsk, Ukraine (P.K.) University Hospital Brno, Brno, Czech Republic (L.P.) University Hospitals Birmingham NHS Foundation Trust, Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.) - both in the United Kingdom the Department of Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland (S.G.) Clínica de Tratamento E, Cuiaba, Brazil (A.C.) Andrew Love Cancer Centre, Geelong, VIC, Australia (P.C.) Clinic of Professional Pathology, Saratov, Russia (T.S.) the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.) LTD "Medinvent" Institute of Health, Tbilisi, Georgia (G.I.) Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.) Janssen Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.) and Janssen Research and Development, Raritan, NJ (J.W., H.N.)
-
Lucio, Paulo
Autor Lucio, Paulo From University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca (M.-V.M.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona (J.S.-M.) - both in Spain National and Kapodistrian University of Athens, Athens (M.A.D.) the Institute of Hematology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera "Santa Maria," Terni (A.M.L.) - both in Italy Japanese Red Cross Medical Center, Department of Hematology, Tokyo (K.S.) University of Chicago Medical Center, Chicago (A.J.) Würzburg University Medical Center, Würzburg, Germany (S.K.) Université Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both in Belgium Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.) Semmelweis Egyetem, Budapest, Hungary (Z.N.) Dnepropetrovsk City Clinical Hospital #4, Dnepropetrovsk, Ukraine (P.K.) University Hospital Brno, Brno, Czech Republic (L.P.) University Hospitals Birmingham NHS Foundation Trust, Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.) - both in the United Kingdom the Department of Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland (S.G.) Clínica de Tratamento E, Cuiaba, Brazil (A.C.) Andrew Love Cancer Centre, Geelong, VIC, Australia (P.C.) Clinic of Professional Pathology, Saratov, Russia (T.S.) the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.) LTD "Medinvent" Institute of Health, Tbilisi, Georgia (G.I.) Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.) Janssen Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.) and Janssen Research and Development, Raritan, NJ (J.W., H.N.)
-
Nagy, Zsolt
Autor Nagy, Zsolt From University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca (M.-V.M.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona (J.S.-M.) - both in Spain National and Kapodistrian University of Athens, Athens (M.A.D.) the Institute of Hematology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera "Santa Maria," Terni (A.M.L.) - both in Italy Japanese Red Cross Medical Center, Department of Hematology, Tokyo (K.S.) University of Chicago Medical Center, Chicago (A.J.) Würzburg University Medical Center, Würzburg, Germany (S.K.) Université Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both in Belgium Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.) Semmelweis Egyetem, Budapest, Hungary (Z.N.) Dnepropetrovsk City Clinical Hospital #4, Dnepropetrovsk, Ukraine (P.K.) University Hospital Brno, Brno, Czech Republic (L.P.) University Hospitals Birmingham NHS Foundation Trust, Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.) - both in the United Kingdom the Department of Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland (S.G.) Clínica de Tratamento E, Cuiaba, Brazil (A.C.) Andrew Love Cancer Centre, Geelong, VIC, Australia (P.C.) Clinic of Professional Pathology, Saratov, Russia (T.S.) the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.) LTD "Medinvent" Institute of Health, Tbilisi, Georgia (G.I.) Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.) Janssen Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.) and Janssen Research and Development, Raritan, NJ (J.W., H.N.)
-
Kaplan, Polina
Autor Kaplan, Polina From University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca (M.-V.M.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona (J.S.-M.) - both in Spain National and Kapodistrian University of Athens, Athens (M.A.D.) the Institute of Hematology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera "Santa Maria," Terni (A.M.L.) - both in Italy Japanese Red Cross Medical Center, Department of Hematology, Tokyo (K.S.) University of Chicago Medical Center, Chicago (A.J.) Würzburg University Medical Center, Würzburg, Germany (S.K.) Université Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both in Belgium Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.) Semmelweis Egyetem, Budapest, Hungary (Z.N.) Dnepropetrovsk City Clinical Hospital #4, Dnepropetrovsk, Ukraine (P.K.) University Hospital Brno, Brno, Czech Republic (L.P.) University Hospitals Birmingham NHS Foundation Trust, Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.) - both in the United Kingdom the Department of Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland (S.G.) Clínica de Tratamento E, Cuiaba, Brazil (A.C.) Andrew Love Cancer Centre, Geelong, VIC, Australia (P.C.) Clinic of Professional Pathology, Saratov, Russia (T.S.) the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.) LTD "Medinvent" Institute of Health, Tbilisi, Georgia (G.I.) Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.) Janssen Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.) and Janssen Research and Development, Raritan, NJ (J.W., H.N.)
NLK
ProQuest Central
od 1980-01-03 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
Health & Medicine (ProQuest)
od 1980-01-03 do Před 3 měsíci
Family Health Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
Psychology Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
Health Management Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
Public Health Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
PubMed
29231133
DOI
10.1056/nejmoa1714678
Knihovny.cz E-zdroje
BACKGROUND: The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. Daratumumab has shown efficacy in combination with standard-of-care regimens in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 3 trial, we randomly assigned 706 patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation to receive nine cycles of bortezomib, melphalan, and prednisone either alone (control group) or with daratumumab (daratumumab group) until disease progression. The primary end point was progression-free survival. RESULTS: At a median follow-up of 16.5 months in a prespecified interim analysis, the 18-month progression-free survival rate was 71.6% (95% confidence interval [CI], 65.5 to 76.8) in the daratumumab group and 50.2% (95% CI, 43.2 to 56.7) in the control group (hazard ratio for disease progression or death, 0.50; 95% CI, 0.38 to 0.65; P<0.001). The overall response rate was 90.9% in the daratumumab group, as compared with 73.9% in the control group (P<0.001), and the rate of complete response or better (including stringent complete response) was 42.6%, versus 24.4% (P<0.001). In the daratumumab group, 22.3% of the patients were negative for minimal residual disease (at a threshold of 1 tumor cell per 105white cells), as compared with 6.2% of those in the control group (P<0.001). The most common adverse events of grade 3 or 4 were hematologic: neutropenia (in 39.9% of the patients in the daratumumab group and in 38.7% of those in the control group), thrombocytopenia (in 34.4% and 37.6%, respectively), and anemia (in 15.9% and 19.8%, respectively). The rate of grade 3 or 4 infections was 23.1% in the daratumumab group and 14.7% in the control group; the rate of treatment discontinuation due to infections was 0.9% and 1.4%, respectively. Daratumumab-associated infusion-related reactions occurred in 27.7% of the patients. CONCLUSIONS: Among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation, daratumumab combined with bortezomib, melphalan, and prednisone resulted in a lower risk of disease progression or death than the same regimen without daratumumab. The daratumumab-containing regimen was associated with more grade 3 or 4 infections. (Funded by Janssen Research and Development; ALCYONE ClinicalTrials.gov number, NCT02195479 .).
- MeSH
- analýza podle původního léčebného záměru MeSH
- bortezomib aplikace a dávkování MeSH
- dospělí MeSH
- infekce chemicky indukované mortalita MeSH
- Kaplanův-Meierův odhad MeSH
- lidé středního věku MeSH
- lidé MeSH
- melfalan aplikace a dávkování MeSH
- míra přežití MeSH
- mnohočetný myelom farmakoterapie mortalita MeSH
- monoklonální protilátky aplikace a dávkování škodlivé účinky MeSH
- následné studie MeSH
- prednison aplikace a dávkování MeSH
- přežití po terapii bez příznaků nemoci MeSH
- protokoly antitumorózní kombinované chemoterapie škodlivé účinky terapeutické užití MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
Sdílet
Název dokumentu
Po ukončení testovacího provozu bude odkaz přesměrován adresu produkční verze portálu Medvik.